Trials / Recruiting

RecruitingNCT06664775

A Study to Compare the Efficacy and Safety of TachoSil and Surgicel Original as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery

An Open Label, Prospective, Randomized, Parallel Groups, Multicenter Study to Compare the Efficacy and Safety of TachoSil® Versus Surgicel™ Original (Oxidized Regenerated Cellulose) as an Adjunct to Control Mild to Moderate Soft Tissue Bleeding During Surgery.

Status: Recruiting
Phase: Phase 3
Study type: Interventional
Enrollment: 116 (estimated)

Sponsor: Corza Medical GmbH · Industry
Sex: All
Age: 1 Month
Healthy volunteers: Not accepted

Summary

The purpose of this clinical study is to assess the efficacy and safety of TachoSil compared to the widely known and used for \> 60 years local hemostatic product Surgicel Original as an adjunct to control mild to moderate soft tissue bleeding during surgery.

Conditions

Hemorrhage

Interventions

Type	Name	Description
BIOLOGICAL	TachoSil	Adjunct to hemostasis
BIOLOGICAL	Surgicel Original	Adjunct to hemostasis

Timeline

Start date: 2025-04-02
Primary completion: 2026-03-31
Completion: 2026-06-30
First posted: 2024-10-30
Last updated: 2025-10-06

Locations

9 sites across 1 country: United States

Regulatory

FDA-regulated drug study

Source: ClinicalTrials.gov record NCT06664775. Inclusion in this directory is not an endorsement.